Daniel J. Moorhead Sells 10,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $7.88, for a total value of $78,800.00. Following the completion of the transaction, the chief financial officer now directly owns 26,299 shares in the company, valued at approximately $207,236.12. The trade was a 27.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zynex Stock Performance

Shares of ZYXI traded up $0.28 during mid-day trading on Friday, reaching $8.09. The company had a trading volume of 50,575 shares, compared to its average volume of 68,037. The stock has a 50 day moving average of $8.30 and a two-hundred day moving average of $8.37. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $257.63 million, a P/E ratio of 53.93 and a beta of 0.49. Zynex, Inc. has a 52-week low of $7.15 and a 52-week high of $13.77.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. During the same period in the previous year, the business posted $0.10 EPS. The business’s revenue was up .1% compared to the same quarter last year. On average, analysts expect that Zynex, Inc. will post 0.2 earnings per share for the current year.

Institutional Investors Weigh In On Zynex

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYXI. Gladius Capital Management LP raised its position in shares of Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after purchasing an additional 1,742 shares during the last quarter. Investment Partners Asset Management Inc. purchased a new position in shares of Zynex in the third quarter valued at approximately $96,000. Hsbc Holdings PLC acquired a new stake in shares of Zynex in the second quarter worth approximately $113,000. Quest Partners LLC increased its position in shares of Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after purchasing an additional 11,195 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Zynex by 10.4% in the 2nd quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock valued at $182,000 after purchasing an additional 1,846 shares in the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Royal Bank of Canada dropped their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.